Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 8/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.34 |
| ▸ | CDK2 | P24941 | 2/20 | 0.34 |
| ▸ | RAF1 | P04049 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PRCP | P42785 | 1/20 | 0.30 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.30 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23994249 | 0.91 | NT5E (0.43) | NT5EALDH1A1SYKCCNE1CDK2 | |
| SCHEMBL23993668 | 0.89 | NT5E (0.42) | NT5EALDH1A1CCNE1CDK2LMNA | |
| SCHEMBL23993703 | 0.89 | NT5E (0.42) | NT5EALDH1A1CCNE1CDK2LMNA | |
| SCHEMBL25004844 | 0.89 | NT5E (0.42) | NT5EALDH1A1CCNE1CDK2LMNA | |
| SCHEMBL23993727 | 0.88 | NT5E (0.42) | NT5EALDH1A1CCNE1CDK2RAF1 | |
| SCHEMBL23993879 | 0.88 | NT5E (0.40) | NT5EALDH1A1SYKCCNE1CDK2 | |
| SCHEMBL23995428 | 0.88 | NT5E (0.42) | NT5EALDH1A1CCNE1CDK2RAF1 | |
| SCHEMBL23993257 | 0.88 | NT5E (0.42) | NT5EALDH1A1CCNE1CDK2RAF1 | |
| SCHEMBL23995538 | 0.88 | NT5E (0.40) | NT5EALDH1A1CCNE1CDK2RAF1 | |
| SCHEMBL23995299 | 0.88 | NT5E (0.40) | NT5EALDH1A1SYKCCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| WO-2021222522-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | NT5E 3/4885ALDH1A1 347/4885SYK 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.